Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma

40Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

Abstract

The management of hepatocellular carcinoma (HCC) is evolving because of recently introduced novel therapeutic approaches. There is growing recognition that optimal outcome requires choosing treatment tailored to suit each individual patient, necessitating an early and accurate assessment of tumor response to therapy. The established and adapted image biomarkers based on size for tumor burden measurement continues to be applied to HCC as size measurement can easily be used in any clinical practice. However, in the setting of novel targeted therapies and liver directed treatments, simple tumor anatomical changes can be less informative and usually appear later than biological changes. Therefore the importance of image biomarkers such as tumor viability measurement, functional perfusion and diffusion imaging for response assessment is increasingly being recognized. Although promising, these imaging biomarkers have not gone through all the required steps of standardization and validation. In this review, we discuss various established, evolving and emerging imaging biomarkers and the criteria of response evaluation and their challenges in HCC. © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Cite

CITATION STYLE

APA

Jiang, T., Zhu, A. X., & Sahani, D. V. (2013, January). Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2012.08.022

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free